Letters
NHS limiting access to high priced drugs
Drug appraisal issues must be resolved at policy level
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4519 (Published 23 August 2016) Cite this as: BMJ 2016;354:i4519
- Katharina Kieslich, research associate1,
- Peter Littlejohns, professor of public health1,
- Albert Weale, emeritus professor of political theory and public policy2
- 1King’s College, London, Division of Health and Social Care Research, Addison House, Guy’s Campus, London SE1 1U, UK
- 2School of Public Policy, University College London, London WC1H 9QU, UK
- katharina.kieslich{at}kcl.ac.uk
Gornall and colleagues’ investigation shows that stakeholders blame NHS England (NHSE) for slow and limited access to new hepatitis C medicines.1 However, NHSE’s tactics reflect a fundamental challenge that the medicines appraisal system in England faces: the new hepatitis C medicines have, in one fell swoop, challenged the cost effectiveness paradigm that is perceived as …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.